Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Holding ADCT?
Track your performance easily
ADCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $6.04
Previous Close$3.1
Volume144.17K
Average Volume (3M)606.32K
Market Cap
$320.93M
Enterprise Value$122.58M
Total Cash (Recent Filing)$300.10M
Total Debt (Recent Filing)$123.01M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 05, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.56
Shares Outstanding96,647,450
10 Day Avg. Volume296,234
30 Day Avg. Volume606,315
Standard Deviation0.28
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-2.28
Price to Sales (P/S)8.50
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.10
Enterprise Value/Gross Profit1.84
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$8.33Price Target Upside150.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ADC Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of glofit plus Zynlonta could be a true game changer in DLBCL.
Financial PerformanceADCT actually achieved commercial brand profitability with revenues of $34.9MM YTD.
Operational RunwayADC Therapeutics ended with $300.1M in cash and cash equivalents, providing an operational runway through multiple data catalysts.
Bears Say
Net LossADCT reported results with a net loss of ($36.5MM).
Quarterly SalesZYNLONTA's quarterly sales were $17.0M, which is lower than the prior quarter's sales of $17.8M and below the forecasted $19.0M.
Sales DecreaseZynlonta net product sales were $17MM, representing a 5% quarter-over-quarter decrease in sales, in part due to variability in ordering patterns.
---
Ownership Overview
32.15% Insiders
9.09% Mutual Funds
42.08% Other Institutional Investors
16.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $0.36 and its highest was $6.04 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
Currently, no data Available
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on Aug 06, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.457 by $0.077.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -$0.38.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 96,666,750 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.457. Following the earnings report the stock price went up 1.742%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Among the largest hedge funds holding ADC Therapeutics Ltd’s share is Grosvenor Holdings, L.L.C.. It holds ADC Therapeutics Ltd’s shares valued at 5M.
---
ADC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (150.90% Upside)
$8.33 (150.90% Upside)
Blogger Sentiment
Bullish
ADCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
300.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.71%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
---
ADCT Company Deck
---
ADCT Earnings Call
Q2 2024
0:00 / 0:00
---
ADCT Stock 12 Month Forecast
Average Price Target
$8.33
▲(150.90% Upside)
Technical Analysis
Best Analysts Covering ADCT
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
+26.48%
assigned a buy rating last month
Copying Gregory Renza's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +26.48% per trade.
---